Elanco Animal Health (NYSE:ELAN) (NYSE: ELAN) is a global leader in animal health, dedicated to improving the health and well-being of livestock and companion animals. Founded in 1954 as a division of Eli Lilly and Company, Elanco became an independent, publicly traded company in 2018. Since then, it has pursued a clear mission to develop innovative solutions that help farmers and pet owners enhance productivity, safeguard animal welfare, and address growing protein needs worldwide.
The company’s portfolio encompasses a broad range of products and services across parasiticides, vaccines, antimicrobials, feed additives and digital technologies. In the livestock segment, Elanco offers nutritional and health management solutions for poultry, swine, cattle and aquaculture, aiming to optimize growth performance, disease prevention and food safety. In the companion animal segment, the company provides prescription and over-the-counter treatments for fleas, ticks, heartworm and various other parasitic and infectious diseases. Elanco also invests in data-driven platforms and telehealth tools designed to help veterinarians and producers make more informed decisions on animal health management.
With operations in over 90 countries, Elanco’s research, manufacturing and commercial footprint spans North America, Europe, Latin America, Asia Pacific and the Middle East. The company collaborates with academic institutions, research consortia and industry partners to accelerate discovery and regulatory approvals. Headquartered in Greenfield, Indiana, Elanco is led by President and Chief Executive Officer Jeffrey N. Simmons, under whose leadership the company has strengthened its global reach and product pipeline. Guided by a commitment to sustainability, Elanco aims to deliver long-term value by addressing the critical challenge of feeding a growing population while promoting responsible use of animal health products.
